Capitalizing on Cellular Therapies in Lymphoma and Myeloma

In our exclusive interview, Kansagra, D’Souza, and Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.